Consensus Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
12.48 ^USD	-3.41%		-5.67%	+32.62%

Feb. 09	Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	MT
Feb. 07	Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024

Evolution of the average Target Price on Enanta Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b986ab4fde50299e13aa582d8.-DqmJqPTeTaFz3qay9o29YHWbAQ3fGNgamxqdmRTp4I.l3HuH46dDADCpSXTvrJ-u9XmPHJjGC4pCyMODC8j0cjIaudU1b8MDsb_Tg~69f15049f283d0d038621beeca3a6647

Analyst Recommendations on Enanta Pharmaceuticals, Inc.

Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	Feb. 09	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating	Nov. 22	MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating	Nov. 21	MT
HC Wainwright Adjusts Enanta Pharmaceuticals Price Target to $30 From $48, Maintains Buy Rating	23-10-23	MT
Enanta Pharmaceuticals Receives Speculative Risk Qualifier on Sector Perform Rating From RBC, Price Target Cut to $15 From $25	23-10-02	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $25 From $30, Maintains Perform Rating	23-08-09	MT
JMP Securities Lowers Price Target on Enanta Pharmaceuticals to $42 From $65, Maintains Market Outperform Rating	23-08-08	MT
Jefferies Downgrades Enanta Pharmaceuticals to Hold From Buy, Adjusts Price Target to $18 From $49	23-08-08	MT
RBC Cuts Enanta Pharmaceuticals' Price Target to $25 From $33, Keeps Sector Perform Rating	23-07-07	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $30 From $50, Maintains Perform Rating	23-05-11	MT
JMP Securities Adjusts Price Target on Enanta Pharmaceuticals to $65 From $82, Keeps Market Outperform Rating	23-05-09	MT
HC Wainwright Adjusts Enanta Pharmaceuticals' Price Target to $48 From $68, Keeps Buy Rating	23-05-09	MT
JMP Securities Adjusts Enanta Pharmaceuticals' Price Target to $65 From $82, Keeps Market Outperform Rating	23-05-09	MT
RBC Cuts Price Target on Enanta Pharmaceuticals to $33 From $48, Maintains Sector Perform Rating	23-05-09	MT
RBC Capital Adjusts Enanta Pharmaceuticals Price Target to $48 From $54, Maintains Sector Perform Rating	23-04-06	MT
RBC Lifts Price Target on Enanta Pharmaceuticals to $54 From $52, Maintains Sector Perform Rating	23-02-28	MT
JPMorgan Adjusts Enanta Pharmaceuticals Price Target to $60 From $74, Maintains Neutral Rating	23-02-08	MT
RBC Raises Enanta Pharmaceuticals' Price Target $52 From $49, Maintains Sector Perform Rating	23-02-08	MT
SVB Securities Adjusts Enanta Pharmaceuticals' Price Target to $49 From $50, Keeps Market Perform Rating	23-01-27	MT
HC Wainwright Initiates Enanta Pharmaceuticals With Buy Rating, Sets $56 Price Target	22-12-09	MT
RBC Cuts Price Target on Enanta Pharmaceuticals to $54 From $65, Maintains Sector Perform Rating	22-11-22	MT
RBC Trims Price Target on Enanta Pharmaceuticals to $65 From $66, Maintains Sector Perform Rating	22-10-06	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $59 From $53, Maintains Perform Rating	22-08-10	MT
JMP Securities Raises Enanta Pharmaceuticals' Price Target to $137 From $103, Maintains Market Outperform Rating	22-08-09	MT
Oppenheimer Adjusts Enanta Pharmaceuticals' Price Target to $53 From $45, Maintains Perform Rating	22-08-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.48 USD

Average target price

20.88 USD

Spread / Average Target

+67.27%

High Price Target

35 USD

Spread / Highest target

+180.45%

Low Price Target

11 USD

Spread / Lowest Target

-11.86%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Enanta Pharmaceuticals, Inc.

Oppenheimer
HC Wainwright
RBC Capital Markets
JMP Securities
Jefferies & Co.
JPMorgan Chase
SVB Securities LLC
Evercore ISI
Baird
Roth Capital Partners
SVB Leerink
J.P. Morgan Chase

Ratings for Enanta Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar